Tonix医药控股 TNXP 深 沪
等待开盘 05-12 09:30:00 美东时间
14.25
+0.160
+1.14%
华盛通- 最 高15.18
- 今 开13.99
- 成交量 18.50万股
- 最 低 13.455
- 昨 收 14.09
- 总市值 26.70万
- 52周最高 69.9648
- 市盈率 静 --
- 换手率 987.33%
- 52周最低 11.6028
- 委 比 -50.00%
- 总股本 1.87万
- 历史最高 1318400.00
- 量 比 0.68
- 振 幅 12.24%
- 历史最低 0.1006
- 每 手 1
- 风险率 11.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Tonix Pharmaceuticals Shares Are Rallying Wednesday
Tonix Pharmaceuticals Holding shares are trading higher Wednesday after announcing commercial payer coverage for fibromyalgia drug TONMYA.
05-06 20:56
Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting
Tonix shares fell 2% premarket after the Nasdaq Global Select uplisting, with technical indicators signaling short-term weakness.
03-03 20:04
Tonix Unveils Once-Yearly Lyme Prevention Antibody, Eyes FDA Talks In 2026
TNXP announced updates on TNX-4800, a long-acting mAb targeting Lyme disease. Seeking FDA meeting in 2026.
2025-12-30 01:11
Tonix Sells 615,025 Shares at $16.26 Each in $20M Stock Deal With Point72
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully-integrated commercial stage biotechnology company, today announced it has entered into a securities purchase agreement with Point72
2025-12-29 21:01
Why Tonix Pharmaceuticals (TNXP) Stock Jumped Monday Morning
Tonix Pharmaceuticals shares are rising Monday morning after the company announced the U.S. commercial availability of its new drug, TONMYA.
2025-11-17 23:11
Tonix Pharmaceuticals' TONMYATM Now Commercially Available Across U.S.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, announced today that TONMYATM (cyclobenzaprine HCl sublingual tablets) is now
2025-11-17 20:10
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors
Tonix Pharmaceuticals appoints James Hunter to its Board of Directors. Hunter brings over 40 years of experience in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab, and Novartis. He led the launch of Tonix Medicines and the acquisition of migraine assets Zembrace and Tosymra. His appointment strengthens Tonix’s commercial strategy as it prepares for the potential launch of TNX-102 SL for fibromyalgia later this year.
2025-06-13 11:00
Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention
Tonix Pharmaceuticals的CEO Seth Lederman将于2025年6月16日在波士顿BIO大会上演讲，介绍公司专注于疼痛管理及疫苗开发，包括纤维肌痛治疗药物TNX-102 SL的最新进展。
2025-06-10 11:00
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025
Tonix Pharmaceuticals announced a poster presentation at EULAR 2025 focusing on TNX-102 SL, a sublingual cyclobenzaprine formulation targeting fibromyalgia. The presentation, by Iredell Iglehart, M.D., highlights the drug's effects on non-restorative sleep and sustained pain reduction.
2025-06-05 11:00
Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase
Tonix Pharmaceuticals Holding Corp. announced that its CEO, Seth Lederman, participated in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase. The company is focused on developing therapies for pain management and vaccines addressing public health challenges. Notably, TNX-102 SL, a candidate for fibromyalgia management, has received FDA’s Fast Track designation and an August 15, 2025 PDUFA goal date. Tonix also operates a state-of-the-art infectious disease research facility.
2025-05-22 11:00
